Crossject Société Anonyme (ALCJ.PA)
| Previous Close | 2.4850 |
| Open | 2.4650 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 2.3000 - 2.4650 |
| 52 Week Range | 1.5200 - 5.9600 |
| Volume | |
| Avg. Volume | 58,547 |
| Market Cap | 109.872M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | Sep 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.20 |
GlobeNewswireCrossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization
Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafterCrossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that year Dijon, France, October 22 2024 (07:30 CET) - Crossject (IS
- GlobeNewswire
Crossject announces its eligibility for France’s PEA-PME investment scheme
Enables French retail investors to buy securities under preferential tax conditions Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®, today confirms its eligibility for PEA-PME, a French government investment scheme which enables retail investors to acquire a portfolio of European securities whilst benefiting from preferential tax co
- GlobeNewswire
Crossject reports financial results and business highlights for the first six months of 2024
Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the Emergency Use Authorization for its epilepsy rescue therapy in early 2025 Dijon, France, September 23, 2024 18:00 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergen
